204 related articles for article (PubMed ID: 17388715)
1. Study design factors and patient demographics and their effect on the decline of placebo-treated subjects in randomized clinical trials in Alzheimer's disease.
Gold M
J Clin Psychiatry; 2007 Mar; 68(3):430-8. PubMed ID: 17388715
[TBL] [Abstract][Full Text] [Related]
2. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial.
De Jesus Moreno Moreno M
Clin Ther; 2003 Jan; 25(1):178-93. PubMed ID: 12637119
[TBL] [Abstract][Full Text] [Related]
3. The Alzheimer's Disease Assessment Scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials.
Doraiswamy PM; Bieber F; Kaiser L; Krishnan KR; Reuning-Scherer J; Gulanski B
Neurology; 1997 Jun; 48(6):1511-7. PubMed ID: 9191757
[TBL] [Abstract][Full Text] [Related]
4. Predictors of placebo group decline in the Alzheimer's disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer's disease.
Irizarry MC; Webb DJ; Bains C; Barrett SJ; Lai RY; Laroche JP; Hosford D; Maher-Edwards G; Weil JG
J Alzheimers Dis; 2008 Jul; 14(3):301-11. PubMed ID: 18599956
[TBL] [Abstract][Full Text] [Related]
5. Galantamine for Alzheimer's disease.
Olin J; Schneider L
Cochrane Database Syst Rev; 2001; (1):CD001747. PubMed ID: 11279727
[TBL] [Abstract][Full Text] [Related]
6. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
[TBL] [Abstract][Full Text] [Related]
7. APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease.
Aerssens J; Raeymaekers P; Lilienfeld S; Geerts H; Konings F; Parys W
Dement Geriatr Cogn Disord; 2001; 12(2):69-77. PubMed ID: 11173877
[TBL] [Abstract][Full Text] [Related]
8. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
[TBL] [Abstract][Full Text] [Related]
9. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies.
Mecocci P; Bladström A; Stender K
Int J Geriatr Psychiatry; 2009 May; 24(5):532-8. PubMed ID: 19274640
[TBL] [Abstract][Full Text] [Related]
10. The Alzheimer's Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease.
Doraiswamy PM; Kaiser L; Bieber F; Garman RL
Alzheimer Dis Assoc Disord; 2001; 15(4):174-83. PubMed ID: 11723368
[TBL] [Abstract][Full Text] [Related]
11. Current Alzheimer's disease clinical trials: methods and placebo outcomes.
Schneider LS; Sano M
Alzheimers Dement; 2009 Sep; 5(5):388-97. PubMed ID: 19751918
[TBL] [Abstract][Full Text] [Related]
12. Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.
Podhorna J; Krahnke T; Shear M; Harrison JE;
Alzheimers Res Ther; 2016 Feb; 8():8. PubMed ID: 26868820
[TBL] [Abstract][Full Text] [Related]
13. A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer's disease.
Bae CY; Cho CY; Cho K; Hoon Oh B; Choi KG; Lee HS; Jung SP; Kim DH; Lee S; Choi GD; Cho H; Lee H
J Am Geriatr Soc; 2000 Dec; 48(12):1566-71. PubMed ID: 11129744
[TBL] [Abstract][Full Text] [Related]
14. Influence of the severity of cognitive impairment on the effect of the Gnkgo biloba extract EGb 761 in Alzheimer's disease.
Le Bars PL; Velasco FM; Ferguson JM; Dessain EC; Kieser M; Hoerr R
Neuropsychobiology; 2002; 45(1):19-26. PubMed ID: 11803237
[TBL] [Abstract][Full Text] [Related]
15. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.
Morris JC; Cyrus PA; Orazem J; Mas J; Bieber F; Ruzicka BB; Gulanski B
Neurology; 1998 May; 50(5):1222-30. PubMed ID: 9595967
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
[TBL] [Abstract][Full Text] [Related]
17. Folic acid with or without vitamin B12 for cognition and dementia.
Malouf M; Grimley EJ; Areosa SA
Cochrane Database Syst Rev; 2003; (4):CD004514. PubMed ID: 14584018
[TBL] [Abstract][Full Text] [Related]
18. Donepezil for vascular cognitive impairment.
Malouf R; Birks J
Cochrane Database Syst Rev; 2004; (1):CD004395. PubMed ID: 14974068
[TBL] [Abstract][Full Text] [Related]
19. Quantification of disease progression and dropout for Alzheimer's disease.
William-Faltaos D; Chen Y; Wang Y; Gobburu J; Zhu H
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):120-31. PubMed ID: 23211395
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
